A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

NCT05118854 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: AMG 510
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Pemetrexed

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]